---
title: "Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296141006.md"
description: "Mizuho Securities analyst Salim Syed maintained a Buy rating on Century Therapeutics (IPSC) with an $8.00 price target. This follows H.C. Wainwright's August 13 report, which also reiterated a Buy rating but set a lower $5.00 price target. The coverage highlights analyst opinions within the healthcare sector."
datetime: "2026-08-17T16:15:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296141006.md)
  - [en](https://longbridge.com/en/news/296141006.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296141006.md)
generator: "portal-rs"
---

# Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities

Mizuho Securities analyst Salim Syed maintained a Buy rating on Century Therapeutics today and set a price target of $8.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Syed covers the Healthcare sector, focusing on stocks such as Century Therapeutics, Amgen, and Biogen. According to TipRanks, Syed has an average return of 1.6% and a 44.33% success rate on recommended stocks. 

In a report released on August 13, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.

### Related Stocks

- [IPSC.US](https://longbridge.com/en/quote/IPSC.US.md)
- [8411.JP](https://longbridge.com/en/quote/8411.JP.md)
- [MFG.US](https://longbridge.com/en/quote/MFG.US.md)
- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [BIIB.US](https://longbridge.com/en/quote/BIIB.US.md)

## Related News & Research

- [Century Therapeutics Reports Q2 Results, Pipeline Advancements](https://longbridge.com/en/news/295668584.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)
- [Barclays Sticks to Its Buy Rating for Prosus (PROSF)](https://longbridge.com/en/news/296063490.md)
- [Visa, Lockheed Martin And A Health Care Stock On CNBC’s ‘Final Trades’](https://longbridge.com/en/news/296127265.md)
- [BLS data shows fastest-growing jobs through 2034 led by clean energy, healthcare, and tech](https://longbridge.com/en/news/296263775.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**